Table 5

Risk factors for disease persistence and progression in participants with definite or borderline RHD at baseline

Persisted or progressed,
N=29 (78.4%)
Improved,
N=8 (21.6%)
Risk difference,
% (95% CI)
p Value
Demographic
Gender
 Male9 (75)3 (25)5.0 (−24.1 to 34.1)0.52
 Female20 (80)5 (20)
Ethnicity
 iTaukei26 (78.8)7 (21.2)−3.8 (−48.5 to 40.9)0.64
 Fijian of Indian descent3 (75.0)1 (25.0)
Residence
 Urban15 (79.0)4 (21.0)−1.1 (−27.7 to 25.3)0.62
 Rural14 (77.8)4 (22.2)
Age at screening (years)
 <1013 (76.5)4 (23.5)3.5 (−23.2 to 30.2)0.55
 ≥1016 (80.0)4 (20.0)
Length of follow-up (years)
 ≥512 (63.3)7 (36.8)31.3 (7.2 to 55.4)0.03
 <517 (94.4)1 (5.6)
Adherence to antibiotic prophylaxis (%)
 ≥5024 (77.4)7 (22.6)5.9 (−27.3 to 39.2)0.61
 <505 (83.3)1 (16.7)
Echocardiographic
Baseline diagnosis
 Definite14 (70.0)6 (30.0)18.2 (−7.0 to 43.5)0.17
 Borderline15 (88.2)2 (11.8)
Severity at baseline
 Moderate/severe10 (83.3)2 (16.7)−7.3 (−34.2 to 19.6)0.48
 Borderline/mild19 (76.0)6 (24.0)
MR >2 cm
 Yes23 (79.3)6 (20.7)−4.3 (−37.7 to 29.1)0.57
 No6 (75.0)2 (25.0)
Initial MR length
 Mean, cm (SD)2.61 (1.4)2.45 (1.7)n/a0.68
AR >1 cm
 Yes10 (66.7)5 (33.3)19.6 (−8.1 to 47.5)0.15
 No19 (86.4)3 (13.6)
Morphological changes
 ≥119 (76.0)6 (24.0)7.3 (−19.6 to 34.3)0.48
 None10 (83.3)2 (16.7)
  • AR, aortic regurgitation; MR, mitral regurgitation; RHD, rheumatic heart disease.